Xofigo, a newly approved treatment for advanced prostate cancer, delivers a powerful punch of radiation directly to tumor cells that have invaded the bone.
Despite taking a tailored risk assessment tool that factors in family history and personal habits, nearly 20 percent of women did not believe their breast cancer risk, according to a new study from the University of Michigan Comprehensive Cancer Center.
Many of breast cancer patients will receive aggressive treatments that could have little to no effect on their survival.
Results from research at the University of Michigan indicate that if mice have healthy gastrointestinal tract, the chances of surviving high doses of chemotherapy increase.
Experts call for more support for tumor biomarker tests; fixing a vicious cycle will lead to tests that better predict treatment successWritten by Nicole Fawcett
A new, high-risk prostate cancer clinic is available at the University of Michigan Comprehensive Cancer Center for men with fast-growing prostate cancer.
OncoMed Pharmaceuticals, a company started at the University of Michigan in 2004, raised $82 million in an initial public offering.
Certain chronic conditions for which urology practices are well-suited, and in some cases, better equipped, to carry out medical home functions compared to their primary care counterparts, according to a new study led by researchers from the University of Michigan.
University of Michigan Comprehensive Cancer Center researchers believe killing stem cells is key to improving cancer treatment.
Men with low-risk of dying from their prostate cancer increasingly opting for advanced treatment options
Despite being unlikely to benefit, more patients with low risk prostate cancer receiving advanced procedures according to new University of Michigan study in JAMA.